K. Shirakawa
Kobe University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by K. Shirakawa.
Clinical Pharmacology & Therapeutics | 1999
Yusuke Tanigawara; Nobuo Aoyama; Tomoko Kita; K. Shirakawa; Fusao Komada; Masato Kasuga; Katsuhiko Okumura
Omeprazole is used for the treatment of infection caused by Helicobacter pylori, and it is metabolized by the polymorphic cytochrome P4502C19 (CYP2C19). We have found that the anti–H pylori efficacy by the combination of omeprazole and antibiotics is related to the CYP2C19 genotype.
Japanese Journal of Cancer Research | 1999
K. Shirakawa; Kohji Takara; Yusuke Tanigawara; Nobuo Aoyama; Masato Kasuga; Fusao Komada; Toshiyuki Sakaeda; Katsuhiko Okumura
The interaction of docetaxel (“Taxotere”) with P‐glycoprotein (P‐gp) was examined using porcine kidney epithelial LLC‐PK1 and LLC‐GA5‐COL150 cells, overexpressing human P‐gp selectively on the apical plasma membrane by transfection of human MDR1cDNA into the LLC‐PK1 cells. The basal‐to‐apical transport of [14C]docetaxel in LLC‐GA5‐COL150 cells significantly exceeded that in LLC‐PK1 cells, but the apical‐to‐basal transport was decreased in LLC‐GA5‐COL150 cells. The intracellular accumulation after its basal or apical application to LLC‐GA5‐COL150 cells was 4‐ to 20‐fold lower than that of LLC‐PK1 cells. Multidrug resistance (MDR) modulators, i.e., cyclosporin A and SDZ PSC 833, inhibited the basal‐to‐apical transport and increased the apical‐to‐basal transport of [14C] docetaxel in LLC‐GA5‐COL150 cells, but verapamil affected only apical‐to‐basal transport. The intracellular accumulation after basal or apical application to LLC‐GA5‐COL150 cells was also increased by these three MDR modulators. These observations demonstrated that docetaxel is a substrate for human P‐gp, suggesting that docetaxel‐drug interactions occur via P‐gp. The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC‐PK1 cells, which endogenously express P‐gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC‐GA5‐COL150 cells. These observations indicate that it is necessary to consider the Pharmacokinetic and pharmacodynamic interactions of docetaxel via P‐gp.
Digestive Diseases and Sciences | 2000
Daisuke Shirasaka; Nobuo Aoyama; Kazuhiro Satonaka; K. Shirakawa; Hiroshi Yoshida; Toshiyuki Sakai; Takahiro Ikemura; Yukiko Shinoda; Masanori Sakashita; Masaki Miyamoto; Kinnosuke Yahiro; Akihiro Wada; Hisao Kurazono; Toshiya Hirayama; Masato Kasuga
Vacuolating cytotoxin, VacA, is one of the most important pathogenetic factors produced by Helicobacter pylori. However, it is not clear whether the diversity in disease outcome may be ascribed to variations in strain and/or to the host responses to virulence factors. In this study, we analyzed the vacA middle region sequence among 65 Japanese isolates to clarify the variation in strain and assayed antibody titer to VacA by ELISA using purified VacA to evaluate the host response to cytotoxin. The nucleotide sequence identities compared among Japanese isolates were 92.8 ± 3.56%, and compared to 88.3 ± 2.89% in tox+ strains reported in GenBank. Positive correlation was found between the antibody titers and the severity of atrophic change of the stomach. In Japan the nucleotide sequences of the vacA middle region were highly homologous and genetically closer to tox+ strains. Antibody titers and host response to cytotoxin may be associated with atrophy of the stomach.
Gastroenterology | 1995
Takao Tamura; Nobuo Aoyama; K. Satonaka; H. Yoshida; K. Shirakawa; Romi Nobusawa; S. Futami; Y. Honsako; Shinsuke Morimoto; Takatoshi Nakashima; A. Ohmoto; H. Okano; Masaki Miyamoto; Masato Kasuga
Gastroenterology | 1998
Nobuo Aoyama; Tanigawara; T. Kita; S. Sakai; K. Shirakawa; F. Kodama; K. Okumura; Masato Kasuga
Nihon rinsho. Japanese journal of clinical medicine | 1999
Nobuo Aoyama; Daisuke Shirasaka; Toshiyuki Sakai; K. Shirakawa
Gastroenterology | 1998
Daisuke Shirasaka; Nobuo Aoyama; K. Satonaka; S. Shigeta; Hiroshi Yoshida; K. Shirakawa; T. Iida; Toshiyuki Sakai; Y. Shinoda; Takahiro Ikemura; Masanori Sakashita; Masaki Miyamoto; Masato Kasuga
Gastroenterology | 1998
Toshiyuki Sakai; Nobuo Aoyama; K. Satonaka; S. Shigeta; Hiroshi Yoshida; K. Shirakawa; T. Iida; Y. Shinoda; Takahiro Ikemura; Masanori Sakashita; Daisuke Shirasaka; Masaki Miyamoto; Masato Kasuga
Gastroenterology | 1998
Hiroshi Yoshida; Nobuo Aoyama; Y. Shinoda; Masanori Sakashita; Daisuke Shirasaka; Toshiyuki Sakai; K. Shirakawa; T. Iida; Masaki Miyamoto; K. Kasuga
Drug Metabolism and Pharmacokinetics | 1997
Yusuke Tanigawara; Tomoko Kita; Maki Hirono; Fusao Komada; Katsuhiko Okumura; Nobuo Aoyama; K. Shirakawa; Toshiyuki Sakai; Masato Kasuga